FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2591660129> ?p ?o ?g. }

• W2591660129 abstract "Abstract Background Extensive studies have confirmed the efficacy of taxanes in combination with anthracycline-based chemotherapy on breast cancer. However, few studies have assessed the efficacy of weekly taxane–anthracycline regimens on locally advanced breast cancer. This study was to compare the efficacy and safety of a weekly taxane–anthracycline regimen with those of tri-weekly anthracycline-based regimen in patients with locally advanced breast cancer. Methods Patients with locally advanced breast cancer were randomized to receive 4–6 cycles of neoadjuvant chemotherapy with tri-weekly 5-fluorouracil–epirubicin–cyclophosphamide (FEC) regimen or weekly paclitaxel–epirubicin (PE) regimen. The primary endpoint was the pathologic complete response (pCR) rate. Other endpoints included the clinical tumor response, breast-conserving surgery rate, and adverse events. Results Between March 2010 and September 2013, 293 patients were randomized to the FEC ( n = 151) and PE ( n = 142) arms. The overall clinical response rate was significantly higher in the PE arm than in the FEC arm (76.06% vs. 59.95%, P = 0.001). Consistently, the post-chemotherapy pathologic T and N stages were significantly lower in the PE arm than in the FEC arm ( P < 0.001). However, the pCR rate was similar in the two arms (10.61% vs. 12.31%, P = 0.665). Overall, 36 (27.27%) patients in the FEC arm and 6 (35.28%) in the PE arm were qualified for breast-conserving surgery. Most adverse events were comparable in both arms, with more severe neutropenia in the PE arm than in the FEC arm (11.97% vs. 5.96%, P = 0.031). Conclusions In patients with locally advanced breast cancer, weekly PE was not superior to FEC in terms of pCR. However, weekly PE has a higher response rate and superior down-staging effects. On this account, the PE regimen may be considered an alternative option for locally advanced breast cancer. Long-term follow-up data are needed to confirm the efficacy of this regimen on locally advanced breast cancer. Trial registration Chinese clinical trial registry, ChiCTR-TRC-10001043, September 21, 2014" @default.
• W2591660129 created "2017-03-16" @default.
• W2591660129 creator A5029761405 @default.
• W2591660129 creator A5039557924 @default.
• W2591660129 creator A5047061872 @default.
• W2591660129 creator A5048518843 @default.
• W2591660129 creator A5054927824 @default.
• W2591660129 creator A5059240782 @default.
• W2591660129 creator A5060187817 @default.
• W2591660129 creator A5063022734 @default.
• W2591660129 date "2017-03-07" @default.
• W2591660129 modified "2023-10-11" @default.
• W2591660129 title "Weekly taxane–anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial" @default.
• W2591660129 cites W1262485082 @default.
• W2591660129 cites W1495375466 @default.
• W2591660129 cites W1972458722 @default.
• W2591660129 cites W1986292173 @default.
• W2591660129 cites W2001646586 @default.
• W2591660129 cites W2012282022 @default.
• W2591660129 cites W2040349368 @default.
• W2591660129 cites W2051213632 @default.
• W2591660129 cites W2069878819 @default.
• W2591660129 cites W2083296039 @default.
• W2591660129 cites W2087179076 @default.
• W2591660129 cites W2096334407 @default.
• W2591660129 cites W2098333537 @default.
• W2591660129 cites W2101624340 @default.
• W2591660129 cites W2102927853 @default.
• W2591660129 cites W2110409717 @default.
• W2591660129 cites W2120639027 @default.
• W2591660129 cites W2123528875 @default.
• W2591660129 cites W2138613537 @default.
• W2591660129 cites W2151254187 @default.
• W2591660129 cites W2156556190 @default.
• W2591660129 cites W2159791477 @default.
• W2591660129 cites W2168993400 @default.
• W2591660129 cites W2336410037 @default.
• W2591660129 cites W2343589315 @default.
• W2591660129 cites W2597616474 @default.
• W2591660129 cites W4247362909 @default.
• W2591660129 cites W4250179064 @default.
• W2591660129 doi "https://doi.org/10.1186/s40880-017-0196-5" @default.
• W2591660129 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5340016" @default.
• W2591660129 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28270181" @default.
• W2591660129 hasPublicationYear "2017" @default.
• W2591660129 type Work @default.
• W2591660129 sameAs 2591660129 @default.
• W2591660129 citedByCount "10" @default.
• W2591660129 countsByYear W25916601292017 @default.
• W2591660129 countsByYear W25916601292018 @default.
• W2591660129 countsByYear W25916601292019 @default.
• W2591660129 countsByYear W25916601292020 @default.
• W2591660129 countsByYear W25916601292023 @default.
• W2591660129 crossrefType "journal-article" @default.
• W2591660129 hasAuthorship W2591660129A5029761405 @default.
• W2591660129 hasAuthorship W2591660129A5039557924 @default.
• W2591660129 hasAuthorship W2591660129A5047061872 @default.
• W2591660129 hasAuthorship W2591660129A5048518843 @default.
• W2591660129 hasAuthorship W2591660129A5054927824 @default.
• W2591660129 hasAuthorship W2591660129A5059240782 @default.
• W2591660129 hasAuthorship W2591660129A5060187817 @default.
• W2591660129 hasAuthorship W2591660129A5063022734 @default.
• W2591660129 hasBestOaLocation W25916601291 @default.
• W2591660129 hasConcept C121608353 @default.
• W2591660129 hasConcept C126322002 @default.
• W2591660129 hasConcept C141071460 @default.
• W2591660129 hasConcept C143998085 @default.
• W2591660129 hasConcept C168563851 @default.
• W2591660129 hasConcept C203092338 @default.
• W2591660129 hasConcept C2776694085 @default.
• W2591660129 hasConcept C2776802502 @default.
• W2591660129 hasConcept C2777063308 @default.
• W2591660129 hasConcept C2777511904 @default.
• W2591660129 hasConcept C2778336483 @default.
• W2591660129 hasConcept C2778850193 @default.
• W2591660129 hasConcept C2780835546 @default.
• W2591660129 hasConcept C2781413609 @default.
• W2591660129 hasConcept C530470458 @default.
• W2591660129 hasConcept C71924100 @default.
• W2591660129 hasConceptScore W2591660129C121608353 @default.
• W2591660129 hasConceptScore W2591660129C126322002 @default.
• W2591660129 hasConceptScore W2591660129C141071460 @default.
• W2591660129 hasConceptScore W2591660129C143998085 @default.
• W2591660129 hasConceptScore W2591660129C168563851 @default.
• W2591660129 hasConceptScore W2591660129C203092338 @default.
• W2591660129 hasConceptScore W2591660129C2776694085 @default.
• W2591660129 hasConceptScore W2591660129C2776802502 @default.
• W2591660129 hasConceptScore W2591660129C2777063308 @default.
• W2591660129 hasConceptScore W2591660129C2777511904 @default.
• W2591660129 hasConceptScore W2591660129C2778336483 @default.
• W2591660129 hasConceptScore W2591660129C2778850193 @default.
• W2591660129 hasConceptScore W2591660129C2780835546 @default.
• W2591660129 hasConceptScore W2591660129C2781413609 @default.
• W2591660129 hasConceptScore W2591660129C530470458 @default.
• W2591660129 hasConceptScore W2591660129C71924100 @default.
• W2591660129 hasIssue "1" @default.
• W2591660129 hasLocation W25916601291 @default.
• W2591660129 hasLocation W25916601292 @default.
• W2591660129 hasLocation W25916601293 @default.
• W2591660129 hasLocation W25916601294 @default.

• next